DDInter1665 DDInter1435
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Sibutramine {u} (Compound) treats {v} (Disease) obesity
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
Sibutramine {u} (Compound) upregulates {v} (Gene) CDK6
Sibutramine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Sibutramine {u} (Compound) downregulates {v} (Gene) MRPL19
Sibutramine {u} (Compound) causes {v} (Side Effect) Bursitis
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinzaparin
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Sibutramine (Compound) treats obesity (Disease)
Sibutramine (Compound) binds CYP3A4 (Gene)
Sibutramine (Compound) upregulates CDK6 (Gene)
Sibutramine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Sibutramine (Compound) downregulates MRPL19 (Gene)
Sibutramine (Compound) causes Bursitis (Side Effect)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam